High doses of BACE1 inhibitors stymie synaptic activity in mice. Researchers recommend careful dosing in clinical trials.
Having variants in three, or even two, genes for amyotrophic lateral sclerosis brings on symptoms a decade earlier. This also happens in sporadic cases, bringing the very term into question, researchers say.
A study in a mouse model of Alzheimer’s disease proposes that degenerating neurons become more excitable because they lose dendrites.
A micro-immunoelectrode allows researchers measure Aβ levels in the interstitial fluid of mice every 30 seconds.
Basic preclinical discoveries keep meeting vibrant for neurodegenerative disease researchers from around the world
People who took prescription medications for hypertension were less likely than others to develop amyotrophic lateral sclerosis.
At Duke University, researchers discussed how injected stem cells might be tracked and used to treat neurodegenerative diseases.
Aβ and other pathogenic proteins may cause neurodegenerative disease by spreading throughout the brain like infectious diseases spread through populations, according to a new mathematical model.
Thirty-one thousand, two hundred and sixty-three attendees from 86 countries attended the annual Society for Neuroscience meeting in Washington, D.C., November 15-19. Twenty-five symposia, 26 minisymposia, 101 nanosymposia, 667 poster sessions, and numerous lectures, workshops, and satellite events attracted researchers from all walks of neuroscience. If you didn’t soak it all in, or if you opted for the relative calm of the lab this year, then check Alzforum in the coming weeks as Gwyneth Zakaib and Tom Fagan bring you highlights.
Abstracts are due by December 1 for The 3rd Wellcome Trust conference on Biomarkers for Brain Disorders: Challenges and Opportunities, to be held February 1-3, 2015, in Cambridge, U.K. Find instructions for submitting abstracts and further details at the conference website. Attendees must register by January 5, 2015.
Stem cells have not yet been tried in a clinical study for Alzheimer’s disease, but that may be about to change. At a Duke symposium, researchers discussed the move toward trials and barriers that remain.
A recognition that microRNAs may powerfully influence the pathogenesis of frontotemporal dementia was on display at ICFTD conference held last month in Vancouver, Canada. It came amid a rapid stream of genetics news, as well as a deeper exploration of the unusual peptide and RNA biology of the disease-causing C9ORF72 repeat expansions. These topics wrap up Jessica Shugart’s and Gabrielle Strobel’s coverage of the meeting, where 590 scientists from 30 countries exchanged the latest clinical and scientific news on the heterogeneous set of diseases that make up FTLD. Taken together, multi-center cohort studies in Europe and North America, surprising insight into the physiological aspects of these diseases, and the advance of an HDAC inhibitor drug into Phase 2 all created a sense that the FTD field is poised for rapid progress.
- Martin Citron on Pharmacological Inhibition of Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 Can Impair Synaptic Plasticity and Sepcific Cognitive Functions
- Stefan Lichtenthaler on Pharmacological Inhibition of Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 Can Impair Synaptic Plasticity and Sepcific Cognitive Functions
- Michael van Es on Amyotrophic lateral sclerosis onset is influenced by the burden of rare variants in known amyotrophic lateral sclerosis genes.
- Marc Aurel Busche on Dendritic Structural Degeneration Is Functionally Linked to Cellular Hyperexcitability in a Mouse Model of Alzheimer’s Disease.
- Igor Timofeev on Dendritic Structural Degeneration Is Functionally Linked to Cellular Hyperexcitability in a Mouse Model of Alzheimer’s Disease.
- Jeffrey Cummings, Constantine Lyketsos, Pierre Tariot, Anton Porsteinsson and Elaine R Peskind on A New Drug to Calm Agitation, Uncontrollable Laughing and Crying, in Alzheimer’s?
- Benjamin Wolozin on Angiotensin-Converting Enzyme Inhibitors and Amyotrophic Lateral Sclerosis Risk: A Total Population-Based Case-Control Study.